Filing Flows › Champions Oncology (CSBR) › R&D spending
Champions Oncology (CSBR) R&D spending by quarter
Champions Oncology's R&D spending was $2.3M in Q1 FY27 (first quarter fiscal 2027), +11% from Q4 FY26. Over the last 7 quarters it ranged from $1.7M (Q3 FY25) to $2.6M (Q2 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY27 | $2.3M | +11% | +13% |
| Q4 FY26 | $2.1M | -7% | +8% |
| Q3 FY26 | $2.3M | -13% | +32% |
| Q2 FY26 | $2.6M | +26% | — |
| Q1 FY26 | $2.1M | +6% | — |
| Q4 FY25 | $2.0M | +14% | — |
| Q3 FY25 | $1.7M | — | — |
Q1 FY27 at a glance
Champions Oncology, Q1 FY27: revenue $15.2M (+9% year over year), operating margin -2.7%, net loss $426K, operating cash flow −$492K. The chart follows the revenue to costs, profit and cash.
Questions
What is Champions Oncology's R&D spending?
Champions Oncology's R&D spending was $2.3M in Q1 FY27 (first quarter fiscal 2027), +11% from Q4 FY26.
How has Champions Oncology's R&D spending changed?
Over the last 7 quarters it ranged from $1.7M (Q3 FY25) to $2.6M (Q2 FY26).